AfyaIndex
Kenyan Reference & Directory
Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
Drug categories Interaction checker
1 of 3 free lookups remaining Upgrade
New search Medicine profile Alphacalcidol
Check interactions

Clinical medicine profile

Alphacalcidol

Vitamin D analogue (1α-OH)

POM
Evidence state Source-linked Review date not recorded
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • Obtain allergy and medication history.
  • Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
  • Use the lowest effective dose for the shortest appropriate duration.
  • Monitor for expected class adverse effects.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Often 0.25–1 mcg daily titrated to Ca/PTH.

Paediatric

Specialist paediatric.

Renal

Titrate to calcium not CrCl alone.

  • CrCl 0–120: See renal_dose_adjustment; confirm product SmPC.
Hepatic

Caution hypercalcaemia.

03 Clinical use

Use, effects & interactions

Indications

  • Renal bone disease
  • hypoparathyroidism
  • selected rickets.
  • Clinical selection for Alphacalcidol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Vitamin D analogue (1α-OH).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.

Drug interactions

Open multi-drug checker ↗
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.
04 Pharmacology

Mechanism & disposition

Bypasses renal 1α-hydroxylation.

Bypasses renal 1α-hydroxylation.Mechanism is agent-specific.At receptor, enzyme, ion channel, transpor…
Read complete mechanism

Bypasses renal 1α-hydroxylation. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From—
Median—
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceBatch A alphabetical research (INN; confirm vs SmPC/local guidelines); PubChem; Local active-ingredient clinical extract; Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.